Purpose Nanostructured Lipid Carriers (NLCs) loading oxaprozin were developed to address an effective drug packaging and targeted delivery, improving the drug pharmacokinetics and pharmacodynamics properties and avoiding the local gastric side-effects. Macrophages actively phagocyte particles with sizes larger than 200 nm and, when activated, overexpress folate beta receptors -features that in the case of this work constitute the basis for passive and active targeting strategies. Methods Two formulations containing oxaprozin were developed: NLCs with and without folate functionalization. In order to target the macrophages folate receptors, a DSPE-PEG 2000 -FA conjugate was synthesized and added to the NLCs. Results These formulations presented a relatively low polydispersity index (approximately 0.2) with mean diameters greater than 200 nm and zeta potential inferior to −40 mV. The encapsulation efficiency of the particles was superior to 95% and the loading capacity was of 9%, approximately. The formulations retained the oxaprozin release in simulated gastric fluid (only around 10%) promoting its release on simulated intestinal fluid. MTT and LDH assays revealed that the formulations only presented cytotoxicity in Caco-2 cells for oxaprozin concentrations superior to 100 μM. Permeability studies in Caco-2 cells shown that oxaprozin encapsulation did not interfered with oxaprozin permeability (around 0.8×10
ABBREVIATIONS

DSPE-PEG 2000 -FA
Disteroylphosphatidylethanolaminepoly(ethylene glycol) 2000 
INTRODUCTION
Inflammatory diseases, including chronic and acute conditions represent some of the worldwide most widespread disorders. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) are one of the most prescribed drugs for the treatment of these conditions. NSAIDs act by blocking the cyclooxygenases (COX) in a competitive way, inhibiting therefore prostanoids synthesis (1, 2) . NSAIDs analgesic and anti-inflammatory effects are a consequence of their ability to block COX-2 activity. NSAIDs are characterized in two distinct classes according to their ability to selectively block COX-2: Non-selective COX inhibitors that block both COX-1 and COX-2 in a non-selective manner; and COX-2 selective inhibitors that selectively block COX-2 (3, 4) . Due to the capability to block COX, even at mM concentrations, NSAIDs have become indispensable in the treatment of several chronic inflammatory diseases and in pain management (5) . However, despite its beneficial effects, NSAIDs present severe side-effects. Nonselective COX inhibitors, have its main side-effects on the upper gastrointestinal (GI) tract due to the carboxylic acid that generally makes part of these NSAIDs chemical structure which causes gastrointestinal irritation when orally administrated (5) . Besides, they prevent mucosal cytoprotective prostaglandins formation enhancing gastrointestinal toxicity, since non-selective COX inhibitors block COX-1 activity (6, 7) . In inflammation sites the permeability of the vasculature is increased allowing the penetration to the interstitial site of particles that normally would not be able to pass through the vasculature (8, 9 ). This process is generally known as the Enhanced Permeability and Retention (EPR) effect (8, 10) . In order to take advantage of this effect, the drug system size is an important factor and must be between approximately 10 and 200 nm (10, 11) . Other factors such as particle charge, inflammation site temperature (generally hyperthermia is associated with inflammation), elevated elastase levels, high enzymatic activity and the pH of an inflammation site environment (significantly lower than the surrounding environment) may also be used for passive targeting of inflammation (8, 12) .
Although the inflammatory pathways may differ with the inflammation inducer, the macrophages are an essential and common component of these processes which make them an interesting target (8, 12) . Macrophages actively phagocyte particles with sizes superior to 200 nm (8, 10) . The folate receptor (FR), particularly the FR-β, is overexpressed in activated macrophages (13) . It is possible to address this targeting molecule, for example conjugating folic acid (FA) on the nanoparticles surface (10, 14) .
Lipid Nanoparticles (LNs) are nanosized particles with a solid lipid matrix. Its constituents are excipients Generally Regarded As Safe (GRAS) substances (15) . LNs can be mainly divided into two types: Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) (16) (17) (18) (19) . SLNs are biocompatible and biodegradable particles prepared using solid lipids at room and body temperature and stabilized by surfactants. SLNs have a highly ordered crystalline structure and the drugs are loaded between the fatty acid chains, the lipid layers and crystal imperfection (15, 19) . NLCs have been introduced in order to surpass the low payload and drug expulsion of the SLNs. These nanoparticles are constituted by solid lipids and liquid lipids (in small amounts) at the room and body temperature in order to create imperfections in the crystalline structure and larger distances between the fatty acid chains (15) (16) (17) (18) (19) (20) . LNs can be used to incorporate both lipophilic and hydrophilic drugs, due to its high water content, increasing the drug stability and being able to protect photosensitive, moisture sensitive and chemically labile molecules from degradation by environmental factors and also for a targeted and controlled drug release (15, 16, (18) (19) (20) (21) .
Oral administration convenience and patient compliance are two major factors that lead to an increased therapeutic efficacy of orally administered drugs and that help to explain its importance and preference (22) . Since one of the GI tract main functions is to break-down and destroy substances, it is to expect that oral formulations must deal with numerous hurdles (22) . Throughout the GI tract one can observe a high pH range that goes from the extremely acidic gastric environment to a near neutral pH in the large intestine (23) . Also, throughout the GI tract different enzymes are synthesized and released being the GI tract filled with numerous proteolytic enzymes that are able to degrade all kind of substances (24) . Nanoparticles drug encapsulation may help to protect the drugs against the harsh GI environment (pH and enzymes) and also increase mucoadhesion and retention in the GI tract, which can lead to an improved drug uptake (22) .
In this context, this work aimed to develop an innovative NSAID delivery system, based on NLCs functionalized with FA with the main purpose of overcoming the most deleterious side-effects of this drug (gastric disorders) after an oral administration. This delivery system intends to promote a controlled and specific NSAID release. The synthesis of the functionalization agent and the use of NLCs with low production costs may allow overcoming NSAIDs side-effects with an economically viable delivery system. The chosen NSAID was Oxaprozin (Oxa), that is a non-selective COX inhibitor NSAID with effective anti-inflammatory, analgesic and antipyretic effects (25, 26) and the characteristics GI side-effects of the NSAIDs.
MATERIALS AND METHODS
Materials
Precirol Ato 5 was a kind gift from Gattefossé (Gattefossé, France). Miglyol 812 was purchased from Acofarma® (Terrassa, Spain). Tween® 60, Triton™ X-100, Thiazolyl Blue Tetrazolium (MTT), Trypan Blue powder, dimethyl sulfoxide ( D M S O ) ≥ 9 9 . 9 % , O x a p r o z i n ( 4 , 5 -d i p h e n y l -2 -oxazolepropanoic acid; Daypro), acetic acid ≥99.8%, potassium phosphate monobasic, folic acid (FA), triethylamine ( T E A ) , d i c y c l o h e x y l c a r b o d i i m i d e ( D C C ) , Nhydroxysuccinimide (NHS), coumarin 6 (98%), chlorpromazine, filipin, cytochalasin D and Dulbecco's Phosphate Buffered Saline pH 7.4 (PBS) were obtained from Sigma-Aldrich®. Sodium phosphate monobasic monohydrated was acquired from Fluka (Germany). Sodium chloride was purchased from Panreac (Spain). Sodium acetate was from Fluka Analytical (Japan). Sodium hydroxide was obtained from VWR International (Belgium). Acetonitrile (Lichrosolv®) was obtained from MERK (Germany). DSPE-PEG 2000 N-Hydroxysuccinimide ester of folic acid (NHS-FA) was prepared by dissolving, under anhydrous conditions through overnight stirring, in the dark, 1.0 g of FA into a mixture of 40 mL of anhydrous DMSO and 0.5 mL of triethylamine. FA was then mixed with 0.5 g of dicyclohexylcarbodiimide and 0.52 g of N-hydroxysuccinimide and stirred for further 18 h in the dark. The resulting solution was then filtered with a 0.45 μM filter in order to remove the precipitated side product (dicylcohexylurea (DCU)), DMSO and triethylamine were evaporated under vacuum (27, 28) .
Coupling of the FA-NHS stock solution with DSPE-PEG 2000 -NH 2 was accomplished by overnight stirring in the dark under anhydrous conditions of 2 mL of the resulting solution of activated FA with 50 mg of DSPE-PEG 2000 -NH 2 dissolved in 1 ml of DMSO. After the process DMSO was removed by evaporation under vacuum and the addition of 6 mL of water (28) .
DSPE-PEG 2000 -FA conjugate was then dialyzed against 500 mL of ultrapure water using a dialysis membrane (Cellu.Sep®T1, 3500 NMWCO, Membrane Filtration Products, Inc.; Seguin, TX, USA) for 48 h in order to remove the unconjugated FA (27) 
Nanostructured Lipid Carriers Synthesis
Nanostructured Lipid Carriers were prepared by a modified organic solvent-free emulsification/sonication method combining high shear homogenization in an ultra-turrax, followed by an ultra-sonication.
Briefly, the lipid phase constituted by the solid lipid Precirol Ato 5, the liquid lipid Miglyol 182 and the stabilizer Tween 60 in a ratio of 0.57:0.26:0.17 were melted at a temperature above the phase transition temperature (70°C) under 10 min stirring in a top stirring hotplate (Barnstead International Thermolyne Cimarec® 2; Iowa, USA). For the synthesis of Oxa loaded NLCs, 30 mg of the solid lipid were replaced by 30 mg of Oxa before the melting process. Functionalized nanoparticles were obtained by adding 2% of the total lipid mass (lipids and surfactant) of DSPE-PEG 2000 -FA to the lipid phase. The molten lipid phase was dispersed in 4.4 mL of ultrapure water at the same temperature by high-speed stirring in an ultra-turrax (Ystral X10/20 E3; Ballrechten-Dottingen, Germany) (30 s at 7000 RPM) followed by sonication (Sonics and Material Vibra-Cell™ with a CV-18 probe; Newtown CT, USA) (5 min at 70% intensity). The solutions were cooled and 4.4 mL of ultrapure water at room temperature was added. The formulations were then stored at room temperature.
For the cells uptake and uptake mechanisms assays, fluorescent marked non-functionalized and functionalized NLCs were synthesized with 1% of the total lipid mass (lipids and surfactant) of coumarin 6 was added to the lipid phase.
NLCs Characterization
Particle Size Measurements. The produced nanoparticles were characterized by their mean hydrodynamic diameter and size distribution (polydispersity index) in a Particle Size Analyzer (Brookhaven Instruments Corporation; Software: Particle Sizing v.5 Brookhaven Instruments; Holtsville, NY, USA), operating at a scattering angle of 90°, at 37°C, with dust cut-off set to 30 and refractive index of the particles set to 1.33. Samples were diluted (1:800) in ultra-pure water and the measurements performed by 6 runs of 2 min each and the mean size and polydispersity index of the formulations were obtained.
Zeta Potential Measurements. Characterization of the zeta potential of the particles was performed in a Zeta Potential Analyzer (ZetaPALS, Brookhaven Instruments Corporation, Software: PALS Zeta Potential Analyser v.5, Brookhaven Instruments; Holtsville, NY, USA) operating at a scattering angle of 90°, at 37°C. Samples were diluted (1:800) in ultra-pure water and the measurements performed by 6 runs of 10 cycles each and the zeta potential and standard deviation of the formulations were obtained.
Encapsulation Efficiency (EE).
Formulations where diluted in ultrapure water (1:50) and centrifuged in Amicom® Ultra Centrifugal Filter Devices, ultracel®-50 k (50000 NMWL) (MERK Milipore, Ltd; Cork, Ireland). Centrifugation (Heraeus Multifuge X1R centrifuge, Thermo Fisher Scientific; Germany) was performed with spin at 2664 g for 40 min at 20°C. Free Oxa present in the supernatant was quantified by UV-vis spectroscopy using a V-660 spectrophotometer (Jasco Corporation, Software: Spectra Manager v.2, Jasco Corporation; Easton, MD, USA) at 285 nm.
Oxa encapsulation efficiency was determined by calculating the difference between the total amount of used Oxa to produce the formulations and the amount of free Oxa remaining on the aqueous phase (Eq. 1: Encapsulation Efficiency calculation formula):
Loading Capacity (LC). NLCs loading capacity was calculated using the Oxa encapsulation efficiency as follows (Eq. 2: Loading Capacity calculation formula):
Transmission Electron Microscopy (TEM). Samples were prepared by diluting the formulations in ultrapure water (1:50) and then 10 μL of this solution placed on a cooper-mesh grid and let to rest for 2 min at room temperature after which the water excess was removed. For contrasting, 10 μL of 1% uranyl acetate solution was placed on the grid surface and let to rest for 30 s at room temperature. Solution excess was removed and the samples observed in a JEM-1400
Transmission Electron Microscope (JEOL Ltd., USA) with an accelerating voltage of 80 kV.
Physical Stability Studies. NLCs physical stability was assessed by monitoring for 4 weeks the particles size, zeta potential and EE using the aforementioned methods of characterization.
In Vitro Release Studies
In vitro release studies were performed using a cellulose dialysis bag diffusion technique (Cellu.Sep®T1, 3500 NMWCO, Membrane Filtration Products, Inc.; Seguin, TX, USA) filled with 2 mL of the formulation (functionalized or non-functionalized Oxa loaded nanoparticles, 1:8 in ultrapure water). In order to mimic the particles path in the body after oral administration, samples were incubated at 37°C under gentile stirring (IKA®-Werke RT15-P Hot Stirring Plate; Germany). To simulate the transit from stomach to intestine samples were incubated first for 3 h in 80 mL of fasted state simulated gastric fluid (FaSSGF: NaCl/HCl solution, pH 1.2 with SIF® Powder) and then placed for 4 h in 80 mL of fasted state simulated intestinal fluid (FaSSIF: buffer solution containing potassium dihydrogen phosphate, pH 6.5 with SIF® Powder). From this point some samples were placed in 80 mL of physiologic fluid (buffer solution at pH 7.4, with monopotassium phosphate) until the end of the experience in order to simulate the particles that never reach the inflamed regions. Other samples were placed until the end of the experience in 80 mL inflammatory fluid (buffer solution at pH 5.4, containing acetic acid and sodium acetate) to simulate the release profile of the NLCs in inflamed regions. Finally the rest of the samples were placed for 18 h in 80 mL of the physiologic fluid and then in 80 mL of the inflammatory fluid until the end of the experience in order to mimic the release profile of NLCs that circulate on the blood for a considerable period of time until reaching the inflamed regions.
At regular intervals, 300 μL aliquots were collected for a UV-vis microplate (UV flat bottom Microliter® plates, Thermo Electron Corporation; Vantaa, Finland) and replaced by an equal amount of fresh fluid (correspondent to the one that was being used). Oxa release was analyzed by UV-vis spectroscopy using a microplate reader (BioTek Instruments Inc., Synergy HT, Software: Gen5 v1.08.4, BioTek Instruments Inc.; Winooski, USA) at 285 nm.
Cell Cultures
Caco-2 (ATCC® HTB-37™) cells (human epithelial cells from the intestinal mucosa) and RAW 264.7 (ATCC® TIB-71™) cells (macrophages from mouse) were cultured at 37°C in an 5% CO 2 atmosphere (Unitherm CO 2 
Cell Viability Assay
The effect of the designed NLCs on cell viability was measured using the methylthiazolyldiphenyl-tetratozium bromide (MTT) conversion assay. Caco-2 cells were seeded in 96-well microplates at a density of 1.0×10 4 cells per well in 100 μL supplemented DMEM and incubated for 22 h at 37°C in a 5% CO 2 atmosphere. 100 μL of different concentrations (5, 10, 50, 100, 500 and 1000 μM) of free Oxa, Oxa loaded in functionalized and non-functionalized NLCs and the correspondent amounts of placebo NLCs were added, and cells were incubated for 4 h. Positive (culture medium -DMEM) and negative controls (Triton X-100 1% (v/v) in PBS) were also included. Medium was transferred for a 96-well microplate and stored for the cytotoxicity assay. 200 μL of a MTT solution (0.5 mg/mL in culture medium) were then added to each cell seeded well and incubated for 3 h at 37°C in a 5% CO 2 atmosphere. MTT was then rejected by plate inversion and 200 μL of DMSO were added and incubated for 15 min at 37°C in a 5% CO 2 atmosphere protected from light. Absorbance was read using a microplate reader at 550 and 690 nm for background subtraction. Cell viability was determined according to the following (Eq. 3: Cell viability calculation formula):
Cell Toxicity Assay
The cell toxicity assay analyzes the presence of lactate dehydrogenase (LDH) on the culture medium. The first steps of the LDH assay were equal to those performed on the MTT cell viability assay until the end of the incubation period of the samples with the cells. From here, the medium resulting from the incubation was centrifuged in a Sigma 3k-2 microplates centrifuge, in order to deposit the cellular remains for 10 min at 250 g, at room temperature. After centrifugation, 100 μL of the supernatant were carefully transferred for a new 96-well microplate and 100 μL of the LDH Cytotoxicity Detection Kit reaction mixture was added to each well and let to incubate in the dark for 15 min at room temperature. Absorbance was then read using a microplate reader at 490 nm and 690 for background subtraction. Cytotoxicity was determined according the following (Eq. 4: Cell cytotoxicity calculation formula):
Cell Permeability Studies
Caco-2 cells were seeded on Transwell devices with a density of 4.5×10 5 cells per insert (4.67 cm 2 polycarbonate membrane with 3.0 μm porosity) in supplemented DMEM culture medium. After 21 days of culture, Caco-2 cells form an absorptive polarized monolayer developing an apical brush border and enzyme segregation, so that it can be used to mimic the intestinal endothelium (29) . For each 3 to 4 days, cells were observed on an inverted microscope (Motic AE2000 TRI coupled with a camera Moticam 5 MP; Spain) and the transepithelial electrical resistance (TEER) measured using an epithelial voltammeter (EVOM2, World Precision Instruments, Inc., USA) to evaluate tight junctions formation. Cells were also washed twice with PBS and the culture medium substituted.
For the permeability studies, cells were washed twice with PBS, and FaSSIF (pH 6.5) and the reference medium PBS (pH 7.4) were added to the correspondent inserts and receptor wells. Free Oxa and all the formulations at 100 μM concentration (determined by the cell viability and cytotoxicity assays) diluted on the correspondent medium were incubated on the inserts for 4 h at 37°C in a 5% CO 2 atmosphere. At different times, 160 μL aliquots were collected for a 96-well UV-vis microplate from the receptor well and replaced by the same amount of the correspondent medium. TEER measurements were also performed at each time in order to evaluate the integrity of the tight junctions during the 4 h assay. At the end of the study, 40 μL of a mixture of acetonitrile (92%) and acetic acid (8%) were added in order to dissolve the lipid matrix of the NLCs and expose Oxa in solution to be quantified. Oxa quantification was performed by UV-vis spectroscopy using a microplate reader, at wavelength of 285 nm.
Apparent permeability coefficient (P app ) was calculated as follows (Eq. 5: Apparent permeability coefficient calculation formula):
Where Q is the total amount of permeated Oxa (μg), A is the diffusion area (cm 2 ), C 0 is the initial Oxa concentration (μg/mL) and t is the time of the experience (s).
Cell Uptake Assay
The NLCs uptake into RAW 264.7 cells was studied by flow cytometry. Cells were seeded in 48-well plates at the density of 2.5×10 5 cells per well in 300 μL of supplemented DMEM and incubated at 37°C in a 5% CO 2 atmosphere to allow cell attachment during 24 h. Then, the medium was replaced by 300 μL of fresh medium containing 0.3 mg/mL of the fluorescent marked non-functionalized and functionalized NLCs. After each incubation time, cells were washed twice with PBS, detached with 100 μL of trypsin-EDTA and recovered in 150 μL of fresh culture medium. Cells were then centrifuged at 200 g for 10 min, and then resuspended in 1 μL in a Trypan Blue solution (0.4% (w/v) in PBS) before measurement. Finally, the samples were analyzed by flow cytometry using the BD Accuri C6 (Biosciences, Belgium) under the 488 nm excitation and 530 nm emission wavelengths. For each sample a minimum of 10,000 events were recorded and the autofluorescence of cells in culture medium were used as control. The cell uptake of both fluorescent NLCs formulations was expressed as the geometric mean fluorescence intensity of NLCs into cells.
Cell Uptake Mechanisms Assay
RAW 264.7 cells were seeded in 48-well plates at the density of 2.5×10 5 cells per well in 300 μL of supplemented DMEM and incubated at 37°C in a 5% CO 2 atmosphere for 24 h to allow cell attachment. To investigate whether the cell uptake was energy-dependent, cells were incubated with fluorescent marked nonfunctionalized and functionalized NLCs at 4°C and 37°C for 30 min. Afterward, cells were treated as described earlier for the cell uptake assay.
Inhibition experiments to address cell uptake mechanisms of both NLCs formulations were performed by flow cytometry, focusing on clathrin-or caveolae-mediated endocytosis, phagocytosis and macropinocytosis uptake mechanisms. Uptake in the presence of different inhibitors was investigated on the attached cells, which were incubated with 300 μL of fresh medium containing dilutions of chlorpromazine (10 μg/mL), filipin (1 μg/mL) and cytochalasin D (5 μg/mL) in supplemented DMEM for 30 min at 37°C in a 5% CO 2 atmosphere (30, 31) . Then, 0.3 mg/mL of the fluorescent marked NLCs formulations were added at each well and incubated for 2 h at 37°C. Then, cells were treated for the measurement by flow cytometry as described in the cell uptake assay.
Statistical Analysis
The experiments were performed at least three times and data expressed as mean±SD. Statistical analyses were performed using IBM® SPSS® Statistics software (v.22.0.0.0; IBM, Armonk, NY, USA). Data were analyzed using one-way analysis of variance (ANOVA) and differences between groups compared by Bonferroni and Tukey post-hoc tests with a P value of <0.05 considered statistically significant.
RESULTS AND DISCUSSION
DSPE-PEG 2000 -FA 1 H-NMR Characterization
The successful synthesis of the DSPE-PEG 2000 -FA conjugate was analyzed by 1 H-NMR (Fig. 1) 
Nanoparticles Characterization
From the synthesis process one obtained a milky suspension characteristic of the ultra-sonication lipid nanoparticles synthesis method. These suspensions had low viscosity which is essential to its use. It is also possible to notice color change (from white to yellowish-orange) in the functionalized nanoparticles when compared with the non-functionalized correspondents.
Nanoparticles diameter, polydispersity index, zeta potential, encapsulation efficiency and loading capacity were also evaluated and are summarized on the Table I .
From the obtained data (Table I ) one can conclude that the NLCs diameters were all above 200 nm, meaning that the nanoparticles can be recognized by the macrophages, as desired (8, 10) . Despite the fact that the functionalization process did not interfered with the diameter of the nanoparticles, the Oxa encapsulation leads to the formation of nanoparticles with large diameter than the corresponding placebo which represents an additional evidence of the Oxa encapsulation.
The polydispersity index of the formulations was around 0.2, meaning that formulations are constituted by a welldefined and monodisperse population of nanoparticles with a relatively low variability having into account the high shear homogenization and ultrasound synthesis method (38) . These values also suggest a uniform functionalization process that leads to a small decrease on the polydispersity index.
Zeta potential of the particles that constitute the formulations is greater than |40| mV ensuring the stability of the formulations and revealing that they do not tend to form aggregates, since they are superior to the reference value for stability of the formulations of |30| mV (39) . Oxa encapsulation and the functionalization process did not have significant interference in the zeta potential values and consequently in the stability of the formulations.
The encapsulation efficiency (98% for NLCs + Oxa) and therefore the loading capacity (9% for NLCs + Oxa) are influenced by the functionalization process, leading to slightly lower values of these parameters (95% and 8% encapsulation efficiency and loading capacity values, respectively, for FANLCs + Oxa). However, the differences were very low revealing the high encapsulation efficiency and loading capacity of these nanoparticles. Transmission electron microscopy (TEM) was also used to analyze the formulations. Transmission electron micrographs (Fig. 2) revealed the spherical shape of the nanoparticles and showed that the encapsulation and functionalization process did not considerably affect the particles shape.
From the physical stability studies (Fig. 3 ) one can observe that the formulations only revealed a slight decrease on the size while maintaining the zeta potential and the encapsulation efficiency (data not shown). Nevertheless, at the end of the study the particles still maintain sizes above 200 nm and therefore maintain the capability to be recognized by the macrophages. One can then conclude that the particles are suitable for use for at least 4 weeks. One should also consider that for future oral administration, the formulations should undergo a lyophilization process which may promote the maintenance of the formulations characteristics for longer periods of time.
In Vitro Release Studies
The in vitro Oxa release studies were designed in order to simulate the NLCs path through the body after oral administration.
Analyzing the data (Fig. 4) is possible to observe that Oxa release seems to be superior for functionalized than for nonfunctionalized particles revealing that the functionalization process may promote the Oxa release by interfering with the lipids packing of the particles mainly on the intestinal fluid, leading to a different in vitro release profile for this formulation. Nevertheless, as desired, only a small amount of Oxa is released in gastric medium, around 10%, for both formulations, which may help to reduce Oxa side-effects on the gastric mucosa. Taking into account the encapsulation efficiency of the formulations (about 98 and 95% for NLCs + Oxa and FANLCs + Oxa, respectively) one can observe that most of the released Oxa on gastric fluid corresponds to the nonencapsulated Oxa, proving that, in fact, only a small amount of the entrapped Oxa is being released.
In intestinal fluid, the formulations revealed different release profiles. Functionalized particles tend to release more Oxa in this fluid, up to 70%, while non-functionalized only release approximately 45% of the total Oxa amount. One can observe that the great majority of the encapsulated Oxa is being released on the intestinal fluid. However, this will be absorbed by the intestinal mucosa and distributed throughout the body and exert its systemic effect, similarly to the free Oxa traditional oral administration.
From this stage the release profile tends to stabilize and promote a slow Oxa release for both formulations, in the three conditions (Fig. 4a, b and c) , until the end of the assay without significant differences between the physiologic and inflammatory media (Oxa release around 50 and 75% for NLCs + Oxa and FA-NLCs + Oxa, respectively, in the three conditions). This low release on these media will maintain Oxa inside the NLCs which in conjugation with the NLCs functionalization will possibly allow Oxa to reach the inflamed areas at therapeutic concentrations. Also, at the end of the assay up to 25% of the initial Oxa amount stills entrapped on the functionalized NLCs. Due to the FA functionalization this entrapped Oxa can be delivered to the activated macrophages by targeting. If one considerer the high encapsulation efficiency and the high amount of Oxa used in the NLCs synthesis one can see that the macrophages targeting can be essential on the Oxa localized delivery.
Effect of the NLCs on Cell Viability and Cytotoxicity
In order to evaluate the cell viability and the cytotoxicity of the designed nanoparticles in the intestinal mucosa, MTT and LDH assays were performed using Caco-2 cell line.
From the MTT assay (Fig. 5 ) one can observe that free Oxa at these concentrations does not reveal a cytotoxic effect being the cell viability around 100%. The comparison between the different nanoparticles at different Oxa concentrations reveals that only the highest concentrations tested (500 and 1000 μM Oxa concentration) present, up to some extent, cytotoxicity to the tested cell line in all the NLCs formulations (less than 50% cell viability for 500 μM and less than 40% cell viability for 1000 μM Oxa). Nevertheless, since free Oxa does not present cytotoxicity at these concentrations and that the correspondent amount of placebo formulations for these high concentrations reveals also cytotoxicity, one can conclude that the cytotoxic effect at these concentrations could not result from the presence of Oxa.
LDH assay (Fig. 6 ) reveals that for cells treated only with culture medium, cell death due to membrane disruption corresponds to roughly 40%. Analyzing the data one can observe that this last value is equal to those obtained in the cells incubated with NLCs for all the Oxa concentrations and correspondent placebos. As a result, no significant toxic effect is observed on the LDH assay results, even for the formulations with 500 and 1000 μM Oxa concentration and respective placebos.
From MTT and LDH assays one can conclude that despite a 50% decrease in cellular activity, for the highest concentrations tested, no effect on the cell integrity is observed even for these concentrations. Therefore, the highest concentration of loaded Oxa that one can use without interfere with cellular viability is 100 μM for both functionalized and nonfunctionalized NLCs and their correspondent placebos. This value is in agreement with a previous study in which this Oxa concentration was also used for Oxa combined with cyclodextrin, chitosan and bile components in Caco-2 cell permeability assay without cellular cytotoxicity being revealed (40) .
Cell Permeability Studies
In order to perform intestinal permeability studies, Caco-2 cells were seeded in transwell devices and the monolayer development was followed by inverted microscopy and transepithelial electrical resistance until the 21st day. TEER values obtained at this time (data not shown) were superior to the reference value of 200 Ω.cm 2 which indicated that the monolayer presented characteristics similar to those of the intestinal mucosa (41) , mimicking the intestinal endothelium. Figure 7 illustrates Oxa permeability profile both in PBS and FaSSIF and Table II presents the respective apparent permeability coefficient values after 4 h of assay. Oxa P app values are in agreement with the literature for free Oxa in HBSS at pH 5.5 (40) .
It is possible to observe that Oxa permeability is slightly higher in PBS than in FaSSIF for both free Oxa and all NLCs tested.
FaSSIF mimics the fasted-state intestinal juice because it contains natural micelles composed of bile salts and lecithin, which enhance the dissolution rate and solubility of lipophilic compounds (42, 43) . However, oxaprozin belongs to the Class II of the Biopharmaceutics Classification System, since it is a highly permeable but very low soluble drug (44) . Therefore, oxaprozin has already very high absorption values, whereby the presence of micelles does not seem to considerably alter the permeability of the drug.
It is also possible to observe that Oxa permeability is slightly higher (less than 5%) for free Oxa than for encapsulated Oxa in FaSSIF medium and that in PBS medium there was no significant permeability differences after the 4 h of assay (Fig. 7) . Similar conclusions can be taken from the P app values (Table II) . Hence, the presence of nanoparticles does not considerably influence Oxa permeability. Indeed, from the in vitro release profile one could conclude that the great majority of the encapsulated Oxa was released on the intestinal fluid medium. Thus, most of the Oxa compound absorbed by the intestinal monolayer was on its free form and not encapsulated in the nanoparticles, being in agreements with the obtained results for free Oxa and Oxa loaded nanoparticles. TEER values were also followed over the 4 h assay and compared to the optimal reference value of 200 Ω.cm 2 (data not shown), For the different media used, one could notice a decrease in this parameter (c.a. 30%). However, a TEER decrease does not necessarily reveal a cytotoxic effect since it can be reversible (45) . In fact, the TEER modification was reasonable and can be attributed to the passage of ions through the paracellular route (46) and to the monolayer hydration since the presence of a high water content increase the ion exchange (47) . The TEER decrease is also related to the opening of the tight junctions and since both free Oxa and formulations are reducing the TEER values it is possible that the presence of the Oxa may be somehow facilitating the opening of the tight junctions (48, 49) . These factors all together help to explain the reduction of the monolayer electrical resistance and the higher permeability for free Oxa when compared with Oxa loaded nanoparticles. Figure 8 shows that cell internalization of both formulations occurs, being detected as early as 30 min. after incubation, since high fluorescence intensity values could be measured within the cells. This implies a high uptake during this short incubation period, which demonstrates that nanoparticles translocate rapidly into the macrophages. Namely, a pronounced increase in cell uptake can be observed for FANLCs formulation after 4 h, which continuous over a period of 20 h, while NLCs uptake was complete within 4 h. Thus, FA-NLCs formulation had a more efficient uptake than nonfunctionalized NLCs.
Cell Uptake and Uptake Mechanisms Studies
The uptake of both NLCs formulations for RAW 264.7 cells may be related to the macrophages ability to internalize particles from 50 to 300 nm either by clathrin-, caveolaemediated endocytosis, phagocytosis and macropinocytosis (50) .
To assess if the NLCs uptake is an active energy-dependent process, the cell uptake was analyzed under 4°C and 37°C (Fig. 9) . A significant decrease in the uptake of both Fig. 4 Oxa release in three simulated conditions after oral administration: (a) particles that never reach the inflamed regions, (b) particles immediately retained inflamed regions and (c) particles that circulate on the blood for a considerable period of time until reaching the inflamed regions. Vertical dashed lines represent media change: i) gastric media, ii) intestinal media, iii) physiologic media and iv) inflammatory media. Values represent mean±SD; n=3.
formulations was observed at 4°C indicating that uptake mechanism is an active energy-dependent endocytic process.
In order to obtain information about the uptake mechanism, different uptake inhibitors were used. Chlorpromazine is known to inhibit the clathrin-mediated endocytosis, while filipin is used for the inhibition of the caveolae-mediated uptake. Cytochalasin D, in the other hand, inhibits the macropinocytosis having also a small effect on caveolaemediated uptake (30, 51) .
To determine the uptake mechanism, the fluorescence of cells treated with the respective formulations without any inhibitor was set to 100%. From Fig. 10 one can observe a significant cell-associated fluorescence decrease for both formulations after the incubation with the different uptake inhibitors. Nevertheless, the effect of the inhibitors was lower for the non-functionalized NLCs uptake revealing that these NLCs may be internalized by a non-specific uptake mechanism.
For the FA-NLCs formulation, the cell-associated fluorescence had a significant decrease in the presence of filipin inhibitor when compared with the other inhibitors and nonfunctionalized NLCs, revealing the predominance of the caveolae-mediated uptake mechanism for this formulation.
In fact, it was already described that FA binds to folate receptors that are clustered in caveolae membrane microdomains, which explains the increased uptake of these NLCs and proves the efficiency of the functionalization process (51) .
Furthermore, the mechanisms of caveolar internalization does not lead to lysosomal degradation, being a nonacidic and nondigestive route of internalization and therefore a promising strategy for drug delivery especially if the uptake can be increased, possibly through the use of specific receptors for caveolae such as folic acid (51) .
Conclusions and Future Work
The developed folate functionalized Oxa loaded nanostructured lipid carriers represents a potential effective system able to deliver by oral route Oxa in specific locations, avoiding these NSAID gastric side-effects.
In this work DSPE-PEG 2000 -FA functionalized or nonfunctionalized nanostructured lipid carriers loaded with Oxa were designed as a nanosystem for Oxa delivery. The developed formulations shown to have homogeneous particles size with mean diameters superiors to 200 nm and polydispersity index around 0.2. Zeta potential of the formulations was superior to |40| mV, suggesting stable formulations. Oxa encapsulation efficiency was high (superior to 95%) leading to a high loading capacity of the system (close to 9%).
The in vitro release study revealed that the designed nanosystems insured low Oxa release in simulated gastric fluid (10%) being the great majority released in simulated intestinal fluid and only a small amount released on physiological and inflammatory medium, leaving around 25% of the initial Oxa amount to be delivered on the activated macrophages by FA functionalization.
MTT and LDH assays on Caco-2 cells revealed NLCs cytotoxicity only for high Oxa concentrations being 100 μM the highest Oxa concentration that can be used in order to the NLCs do not have a cytotoxic effect.
Permeability studies in Caco-2 cell lines revealed that Oxa encapsulation does not reduced Oxa permeability through a monolayer of Caco-2 cells simulating the intestinal endothelium. In fact, the lipid particles revealed permeability over time similar to the free Oxa and a similar apparent permeability both in PBS and FaSSIF media.
Cell uptake and uptake mechanisms studies in RAW 264.7 cells revealed that NLCs functionalization resulted in an enhanced cell uptake over time. The uptake mechanism is energy-dependent and mainly based on a caveolae uptake mechanism.
The designed particles and the obtained results suggest that the functionalized formulation enclose a great potential for Oxa oral administration with less significant gastric side-effects. The great majority of the entrapped Oxa is only released on the intestine promoting a systemic effect due to the intestinal uptake of the Oxa released on this medium. A localized Oxa release is also obtained since Oxa encapsulation does not alter its permeability on the intestinal mucosa, allowing the NLCs internalization and the activated macrophages targeting due to FA functionalization of the NLCs. Avoiding Oxa release on gastric fluid and promoting its targeting release, one avoids its contact with the gastric mucosa and its negative effects on it. Despite the obtained results further studies still needed to be conducted and represent the next step of this work. Cytotoxic studies must also be performed in different cell lines (gastric and cardiac) and ultimately the efficacy of the designed nanosystem must be tested in vivo in healthy and disease animal models. 
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